摘要
目的 :探讨扎鲁司特对轻、中度持续哮喘患者的临床疗效。方法 :将 38例患者随机分为扎鲁司特治疗组 (2 1例 )和对照组 (17例 )。治疗组每日口服安可来 (每片含扎鲁司特 2 0mg) ,2 0mg/次 ,2次 /d ;对照组不口服任何药 ,共 4周。结果 :治疗组与对照组比较、治疗组治疗前后比较 ,无临床症状的天数增加 ,喷吸 β2 -受体激动剂次数减少 ,平均晨间峰流速 (PEFam)、平均夜间峰流速 (PEFpm)均有明显改善 (P <0 0 1、P <0 0 1、P <0 0 5、P <0 0 2 5 )。轻度不良反应 1例 (4 76 % )。结论 :扎鲁司特能有效改善轻、中度持续哮喘病人的肺功能和缓解临床症状 ,减少 β2 -受体激动剂用量。
Aim: To observe the influence of oral Zafirlukast on pulmonary functions of the patients with mild to moderate persistent asthma and clinical efficiency of the drug. Methods: Thirty-eight patients were randomly divided into two groups: Zafirlukast group (21 cases) and control group (17 cases). Zafirlukast group received 20mg Accolate (tablets containing 20mg Zafirlukast). Twice daily for 4 weeks. Control group take no drug. Resulfs: Compared with control group the patients in Zafirlukast group symptomless days increased and the puff times of ventolin decresasd (P<0.01). The PEFam. PEFpm imporved significantly (P<0.05). The symptoms in Zafrilukast group imporved significantly after treatment (P<0.05, P<0.025 ) . Conclusin: Zafirlukast can improve the pulmonary function and reduce use times of β_2-agonist in patients with mild to moderate persistent asthma.
出处
《暨南大学学报（自然科学与医学版）》
CAS
CSCD
2003年第4期46-49,共4页
Journal of Jinan University(Natural Science & Medicine Edition)
关键词
扎鲁司特
支气管哮喘
肺功能
Zafirlukast
bronchial asthma
pulmonary function
